117 related articles for article (PubMed ID: 9224335)
1. p53 protein and gene alterations in pathological stage C prostate carcinoma.
Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
[TBL] [Abstract][Full Text] [Related]
2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
3. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
[TBL] [Abstract][Full Text] [Related]
4. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
5. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
7. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.
Al-Maghrabi J; Vorobyova L; Chapman W; Jewett M; Zielenska M; Squire JA
Mod Pathol; 2001 Dec; 14(12):1252-62. PubMed ID: 11743048
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
10. Alterations of p53 are common in early stage prostate cancer.
Downing SR; Russell PJ; Jackson P
Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
[TBL] [Abstract][Full Text] [Related]
11. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens.
Yasunaga Y; Shin M; Fujita MQ; Nonomura N; Miki T; Okuyama A; Aozasa K
Lab Invest; 1998 Oct; 78(10):1275-9. PubMed ID: 9800953
[TBL] [Abstract][Full Text] [Related]
12. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
13. Re: p53 protein and gene alterations in pathological stage C prostate carcinoma.
Moul JW; Bauer JJ; Sesterhenn IA; Stackhouse GB; Srivastava S
J Urol; 1998 May; 159(5):1648-9. PubMed ID: 9554382
[No Abstract] [Full Text] [Related]
14. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
[TBL] [Abstract][Full Text] [Related]
15. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
16. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
[TBL] [Abstract][Full Text] [Related]
17. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
[TBL] [Abstract][Full Text] [Related]
18. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
[TBL] [Abstract][Full Text] [Related]
19. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
